Gilead Shares Surge 2.82% on $1.01B Volume Ranks 96th in Market Activity Amid Pipeline Progress and Strategic Collaborations

Gilead Sciences (GILD) surged 2.82% on October 7, 2025, with a trading volume of $1.01 billion, ranking 96th in market activity for the day. The biopharmaceutical giant's shares gained traction amid renewed investor confidence in its pipeline advancements and strategic collaborations. Analysts noted that the stock's performance aligned with broader sector trends, though its relative volume position indicated moderate short-term liquidity demand.

Recent developments highlighted Gilead's progress in oncology and antiviral therapies, with preliminary data from a Phase III trial of its experimental HIV treatment generating positive market sentiment. Additionally, regulatory updates regarding potential label expansions for its flagship antiviral drugs reinforced long-term growth expectations among institutional investors. The absence of material competitive threats in its core therapeutic areas further supported the stock's upward momentum.

Market participants observed that the company's recent partnership with a European biotech firm to co-develop next-generation gene therapies contributed to the rally. This collaboration, which includes upfront payments and milestone-based revenue-sharing agreements, has positioned Gilead to leverage complementary technologies while expanding its intellectual property portfolio. Short-term traders interpreted these developments as catalysts for sustained earnings visibility.

To perform this back-test accurately, I’ll need a bit more detail so I can set up the data pull and strategy engine correctly: 1. Universe • Do you want all U.S. listed common stocks, or a narrower universe (e.g., S&P 500 constituents, Russell 3000, NASDAQ only, etc.)? 2. Trade timing • Should we simulate buying at each day’s close and selling at the next day’s close, or use opens? • Equal-weight each of the 500 names for that one-day holding period? 3. Data vendor / coverage • Our data interface can retrieve daily volume and price for U.S. stocks, but please confirm that’s acceptable. 4. Benchmarks / metrics • Besides cumulative return, do you also want volatility, max drawdown, Sharpe, etc.? Once I have these details, I’ll generate the retrieval plan, gather the daily “top-500-by-volume” lists, and run the one-day-hold strategy through the back-testing engine.